508 related articles for article (PubMed ID: 33609416)
1. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases.
Yoshida Y; Oyama N; Iino S; Shimizu C; Hasegawa M
J Dermatol; 2021 Jun; 48(6):916-920. PubMed ID: 33609416
[TBL] [Abstract][Full Text] [Related]
2. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
3. Brodalumab for severe hidradenitis suppurativa: a case of clinico-radiologic improvement and literature review.
Vagnozzi E; Bruni M; Esposito M; Fargnoli MC
J Dermatolog Treat; 2023 Dec; 34(1):2270091. PubMed ID: 37842732
[TBL] [Abstract][Full Text] [Related]
4. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study.
Frew JW; Navrazhina K; Grand D; Sullivan-Whalen M; Gilleaudeau P; Garcet S; Ungar J; Krueger JG
J Am Acad Dermatol; 2020 Nov; 83(5):1341-1348. PubMed ID: 32416208
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa.
Tsiogka A; Liakou AI; Agiasofitou E; Gregoriou S; Stratigos A; Rigopoulos D; Kontochristopoulos G
Dermatology; 2023; 239(6):937-941. PubMed ID: 37579735
[TBL] [Abstract][Full Text] [Related]
6. Case report: Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches.
Tampouratzi E; Kanni T; Katsantonis J; Douvali T
F1000Res; 2019; 8():2002. PubMed ID: 33456757
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hidradenitis suppurativa with biologic medications.
Lee RA; Eisen DB
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
[TBL] [Abstract][Full Text] [Related]
8. Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series.
Yen CF; Huang YH; Chi CC
Indian J Dermatol Venereol Leprol; 2021; 87(2):223-226. PubMed ID: 31389375
[TBL] [Abstract][Full Text] [Related]
9. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
Berman HS; Villa NM; Shi VY; Hsiao JL
J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
[TBL] [Abstract][Full Text] [Related]
10. Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.
Aarts P; Dudink K; Vossen ARJV; van Straalen KR; Ardon CB; Prens EP; van der Zee HH
Drugs; 2021 Aug; 81(12):1397-1410. PubMed ID: 34283386
[TBL] [Abstract][Full Text] [Related]
11. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
[TBL] [Abstract][Full Text] [Related]
12. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
Maarouf M; Clark AK; Lee DE; Shi VY
J Dermatolog Treat; 2018 Aug; 29(5):441-449. PubMed ID: 29098911
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa.
Zouboulis CC
Expert Rev Clin Immunol; 2016 Oct; 12(10):1015-26. PubMed ID: 27531618
[TBL] [Abstract][Full Text] [Related]
14. New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.
Molinelli E; Gioacchini H; Sapigni C; Diotallevi F; Brisigotti V; Rizzetto G; Offidani A; Simonetti O
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176138
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept.
Poulin Y
J Cutan Med Surg; 2009; 13(4):221-5. PubMed ID: 19706231
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.
Navrazhina K; Frew JW; Grand D; Williams SC; Hur H; Gonzalez J; Garcet S; Krueger JG
Br J Dermatol; 2022 Aug; 187(2):223-233. PubMed ID: 35191018
[TBL] [Abstract][Full Text] [Related]
17. Biologics for hidradenitis suppurativa: an update.
Włodarek K; Ponikowska M; Matusiak Ł; Szepietowski JC
Immunotherapy; 2019 Jan; 11(1):45-59. PubMed ID: 30702012
[TBL] [Abstract][Full Text] [Related]
18. Advances in biologic and small molecule therapies for hidradenitis suppurativa.
Chen SX; Greif C; Gibson RS; Porter ML; Kimball AB
Expert Opin Pharmacother; 2022 Jun; 23(8):959-978. PubMed ID: 35470765
[TBL] [Abstract][Full Text] [Related]
19. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy.
Shanmugam VK; Mulani S; McNish S; Harris S; Buescher T; Amdur R
Int J Dermatol; 2018 Jan; 57(1):62-69. PubMed ID: 29130482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
